|
SPONSORED RESEARCH AND LICENSE AGREEMENTS (Details) (USD $)
|
1 Months Ended |
3 Months Ended |
0 Months Ended |
|
Aug. 31, 2002
|
Apr. 30, 2013
|
Jan. 31, 2012
|
Oct. 31, 2014
|
Jul. 31, 2012
|
Jun. 30, 2012
|
Dec. 31, 2014
|
Dec. 31, 2013
|
| Collaborative Arrangement [Member] |
|
|
|
|
|
|
|
|
| Collaborations |
|
|
|
|
|
|
|
|
| Maximum amount of contingent payments receivable |
|
|
|
|
|
|
$ 144,000,000rigl_CollaborativeArrangementMaximumAmountOfContingentPaymentReceivable
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
|
|
| Collaborative Arrangement [Member] | Specified Development Events [Member] |
|
|
|
|
|
|
|
|
| Collaborations |
|
|
|
|
|
|
|
|
| Maximum amount of contingent payments receivable |
|
|
|
|
|
|
52,900,000rigl_CollaborativeArrangementMaximumAmountOfContingentPaymentReceivable
/ rigl_AchievementOfMilestoneAxis
= rigl_SpecifiedDevelopmentEventsMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
|
|
| Collaborative Arrangement [Member] | Specified Regulatory Events [Member] |
|
|
|
|
|
|
|
|
| Collaborations |
|
|
|
|
|
|
|
|
| Maximum amount of contingent payments receivable |
|
|
|
|
|
|
53,600,000rigl_CollaborativeArrangementMaximumAmountOfContingentPaymentReceivable
/ rigl_AchievementOfMilestoneAxis
= rigl_SpecifiedRegulatoryEventsMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
|
|
| Collaborative Arrangement [Member] | Specified Product Launch Events [Member] |
|
|
|
|
|
|
|
|
| Collaborations |
|
|
|
|
|
|
|
|
| Maximum amount of contingent payments receivable |
|
|
|
|
|
|
37,500,000rigl_CollaborativeArrangementMaximumAmountOfContingentPaymentReceivable
/ rigl_AchievementOfMilestoneAxis
= rigl_SpecifiedProductLaunchEventsMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
|
|
| Daiichi Sankyo [Member] |
|
|
|
|
|
|
|
|
| Collaborations |
|
|
|
|
|
|
|
|
| Cumulative amount of payments earned under collaborative arrangement |
|
|
|
|
|
|
7,900,000rigl_CollaborativeArrangementCumulativePaymentsEarnedThroughoutArrangement
/ us-gaap_TypeOfArrangementAxis
= rigl_DaiichiSankyoMember
|
|
| Period of collaboration in research phase |
3 years
|
|
|
|
|
|
|
|
| Daiichi Sankyo [Member] | Milestone Achievement Group One [Member] |
|
|
|
|
|
|
|
|
| Collaborations |
|
|
|
|
|
|
|
|
| Collaborative payment received |
|
1,400,000rigl_CollaborativeArrangementPaymentsReceived
/ rigl_AchievementOfMilestoneAxis
= rigl_MilestoneAchievementGroupOneMember
/ us-gaap_TypeOfArrangementAxis
= rigl_DaiichiSankyoMember
|
750,000rigl_CollaborativeArrangementPaymentsReceived
/ rigl_AchievementOfMilestoneAxis
= rigl_MilestoneAchievementGroupOneMember
/ us-gaap_TypeOfArrangementAxis
= rigl_DaiichiSankyoMember
|
|
|
|
|
|
| Astra Zeneca A B Worldwide License Agreement J A K Inhibitor [Member] |
|
|
|
|
|
|
|
|
| Collaborations |
|
|
|
|
|
|
|
|
| Upfront fee received |
|
|
|
|
1,000,000rigl_CollaborativeArrangementUpfrontFeeReceived
/ us-gaap_TypeOfArrangementAxis
= rigl_AstraZenecaABWorldwideLicenseAgreementJAKInhibitorMember
|
|
|
|
| Revenue recognized |
|
|
|
|
|
1,000,000rigl_CollaborativeArrangementRevenueRecognized
/ us-gaap_TypeOfArrangementAxis
= rigl_AstraZenecaABWorldwideLicenseAgreementJAKInhibitorMember
|
|
|
| Collaborative payment received |
|
|
|
2,500,000rigl_CollaborativeArrangementPaymentsReceived
/ us-gaap_TypeOfArrangementAxis
= rigl_AstraZenecaABWorldwideLicenseAgreementJAKInhibitorMember
|
|
|
|
|
| Astra Zeneca A B Worldwide License Agreement J A K Inhibitor [Member] | Specified Development Events [Member] |
|
|
|
|
|
|
|
|
| Collaborations |
|
|
|
|
|
|
|
|
| Collaborative payment received |
|
|
|
|
|
|
5,800,000rigl_CollaborativeArrangementPaymentsReceived
/ rigl_AchievementOfMilestoneAxis
= rigl_SpecifiedDevelopmentEventsMember
/ us-gaap_TypeOfArrangementAxis
= rigl_AstraZenecaABWorldwideLicenseAgreementJAKInhibitorMember
|
5,800,000rigl_CollaborativeArrangementPaymentsReceived
/ rigl_AchievementOfMilestoneAxis
= rigl_SpecifiedDevelopmentEventsMember
/ us-gaap_TypeOfArrangementAxis
= rigl_AstraZenecaABWorldwideLicenseAgreementJAKInhibitorMember
|
| Ber Gen Bio A S Worldwide License Agreement [Member] |
|
|
|
|
|
|
|
|
| Collaborations |
|
|
|
|
|
|
|
|
| Upfront fee received |
|
|
|
|
500,000rigl_CollaborativeArrangementUpfrontFeeReceived
/ us-gaap_TypeOfArrangementAxis
= rigl_BerGenBioASWorldwideLicenseAgreementMember
|
|
|
|
| Revenue recognized |
|
|
|
|
|
$ 500,000rigl_CollaborativeArrangementRevenueRecognized
/ us-gaap_TypeOfArrangementAxis
= rigl_BerGenBioASWorldwideLicenseAgreementMember
|
|
|